ProHeme Diagnostics

AI-powered blood tests transforming how Multiple Sclerosis is diagnosed and managed

ProHeme Diagnostics is redefining Multiple Sclerosis (MS) care through AI-powered, blood-based diagnostics. Leveraging over a decade of proteomics innovation, ProHeme’s proprietary multi-protein assays — dMSmart and pMSmart — enable accurate diagnosis, disease monitoring, and progression prediction from a simple blood test. These assays connect to the cloud-based ProHeme Hub, which applies advanced algorithms to generate clinician-ready reports and longitudinal insights. Validated across three independent clinical cohorts, the platform aims to reduce diagnostic delays and guide treatment decisions, improving outcomes and quality of life for millions of people affected by MS. The company is advancing toward regulatory validation and global diagnostic partnerships.

Achievements:

-Validated across three independent clinical cohorts comprising over 350 MS and control samples, demonstrating strong diagnostic and predictive performance. 💡 Developed two proprietary multi-protein assays — dMSmart® and pMSmart® — supported by the cloud-based ProHeme Hub for AI-driven report generation. 🤝 Established collaborations with leading clinical and diagnostic partners, including Sonic Healthcare, CSIRO, and major Australian universities, to accelerate regulatory validation and commercialisation.

Team: Mehdi Mirzaei - Founder & CEO; Yuyi You - Co-founder & Director.

Mehdi Mirzaei - Founder & CEO